✦ LIBER ✦

Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation

✍ Scribed by Selwyn Odes; Hillel Vardi; Michael Friger; Frank Wolters; Maurice G. Russel; Lene Riis; Pia Munkholm; Patrizia Politi; Epameinondas Tsianos; Juan Clofent; Severine Vermeire; Estela Monteiro; Iannis Mouzas; Giovanni Fornaciari; Jildou Sijbrandij; Charles Limonard; Gilbert Van Zeijl; Colm O’Morain; Bjørn Moum; Morten Vatn; Reinhold Stockbrugger

Book ID: 119759340
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 316 KB
Volume: 131
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2006.05.052

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk of Cancer in Patients With Inflamma

Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Nationwide Population-based Cohort Study With 30 Years of Follow-up Evaluation

✍ Kappelman, Michael D.; Farkas, Dora K.; Long, Millie D.; Erichsen, Rune; Sandler 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 380 KB

PGI23 Cost-Effectiveness of Episodic or

PGI23 Cost-Effectiveness of Episodic or Maintenance Infliximab Versus Standard Treatment in an Incidence Cohort of Crohn's Disease Patients With 10-Years Follow-Up

✍ S. Odes; D. Greenberg; H. Vardi; M. Friger; R. Stockbrugger; P. Munkholm 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

P254 Effect of standard treatment (ST) v

P254 Effect of standard treatment (ST) versus episodic (ET) or maintenance (MT) infliximab on healthcare cost (HC) and quality-adjusted life years (QALYs) in a community-based incidence cohort of adult Crohn's disease patients with 10 years follow-up

✍ S. Odes; H. Vardi; D. Greenberg; M. Friger; R. Stockbrugger; B. Moum; C. O'Morai 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 120 KB